INTRODUCTION
-Statin agents reduce cardiovascular morbidity and mortality; -Studies have shown that less than 40% of patients take 80% or more of prescribed doses 1 year after starting therapy; -Non adherence is likely an important source of preventable CVD; -There is a lack of data of the impact of non adherence to statin agents on clinical issues; -The more difficult question is whether prescription adherence provides a net economic value in real clinical setting; -The potential economic returns are often missed in the public debate over rising prescription drug costs;
OBJECTIVES
The aims of our study were:
-To evaluate the impact of adherence to statin agents on the incidence of cardiovascular issues in primary prevention; -To evaluate the impact of adherence to statin agents on health care costs.
METHODS

Sources of Data:
1) RAMQ databases:
Demographic file lists: age, gender, postal code and year of death.
Medical services file: claims for medical services: nature of medical act, date, site of delivered (office, emergency, hospital) and diagnostic code and costs for acts and procedures;
Pharmaceutical file: data on all prescriptions for covered drugs delivered to patients living in the community including costs. -CHF cases: ICD-9 codes 398. 91, 402.01, 402.11, 402.91, 428.0, 428.1, and 428.9) or use of furosemide alone or with digoxin, ACE inhibitors, spironolactone, or β-blockers.
2) Med-Echo databases:
-Selection of controls: up to 15 controls were randomly selected from the risk set for each case using density sampling -Matching: age and same follow-up time as the case Exposure Assessment Medication possesion ratio (MPR) corresponds to the total of days' supply of medication dispensed in a period, including the switching for another agent, divided by the length of the follow-up period ( years).
MPR was dichotomized by setting MPR threshold at 80%
Statistical Analysis
1) The adjusted odds ratio of cardiovascular events between the two adherence groups was estimated using a adjusted polytomous logistic analysis 2) To assess the robustness of our findings: -Impact of excluding the patients who died or lost their drug insurance coverage within the 3-year period, we ran a sensitivity analysis for a 1-year period of follow-up.
-Sensitivity analysis was done for the thresholds of the adherence groups at 70% and 90%.
3) All models were adjusted for potential predictors (age, sex, social status, diabetes, hypertension, CDS). The analyses were performed on SAS and p < 0.05 was the level of significance.
1)
Total hospitalization costs, medical service costs and drug costs by using an integrated analysis of administrative claims data were measured during a 3-year of follow-up;
1.1) Sum of hospitalization costs (ER services and hospitalization excluding nursing home and home care), 1.2) Sum of medical service costs (included outpatient services, physician services, medical procedures); 1.3) Sum of drug costs included all ambulatory prescriptions;
2) Two types of cost were measured: 2.1) All-cause medical costs 2.2) Disease-related costs: associated with treatment of CVD conditions defined previously; drug, costs were defined by drug classes in prescription claims data;
3) Statistical analyses -The non-adjusted mean costs of medical services, hospitalization and drug-related between both adherence levels were evaluated using t-tests;
-For hospitalization costs, since a substantial proportion of the study population was not hospitalized, a two-part model was applied: the first part estimated the probability of being hospitalized; and the second part estimated the costs of hospitalization among those who had been hospitalized using a multiple regression model -Predicted costs of hospitalization for adherent and non-adherent patient were estimated as the product of the estimated probability of being hospitalized and the expected mean hospitalization costs; -All models were adjusted for covariates described previously and the development of CVD. The analyses were performed on SAS and p < 0.05 was the level of significance. -Risk factors and comorbidities were significant predictors of costs;
RESULTS
STRENGTS -All new incident users;
-Incident cases of CVD by having no CVD in a 5-year period prior to the cohort entry;
-Large database;
-Adjustment for multiple covariates to control for the effects of comorbidity on utilization and cost: age, sex, socioeconomic status, co-morbidity, CVD risk factors as well as having developed a CVD during follow-up to further decrease the bias. THANK YOU
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